S100A8 and susceptibility to pneumonia measurement: The elevated levels of S100A8/A9 in COVID-19 patients, particularly those with severe pneumonia and multi-organ failure, suggest its potential as a biomarker for disease progression, helping to predict which patients may require intensive care or more aggressive treatment [66].